Search Results

Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.

Helsinn Group announces the signing of a new financing agreement with BancaStato, effective from September 2023.

Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announces the publication of real-world evidence of AKYNZEO® (fosnetupitant with palonosetron) injection/for injection in the journal Advances in Therapy.

RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.

Helsinn Group and Juniper Biologics Pte Ltd announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA® in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults.

Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.

RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.